326 related articles for article (PubMed ID: 37554322)
1. Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy.
Lv Z; Luo F; Chu Y
Front Immunol; 2023; 14():1199145. PubMed ID: 37554322
[TBL] [Abstract][Full Text] [Related]
2. The paths and challenges of "off-the-shelf" CAR-T cell therapy: An overview of clinical trials.
Moradi V; Omidkhoda A; Ahmadbeigi N
Biomed Pharmacother; 2023 Dec; 169():115888. PubMed ID: 37979380
[TBL] [Abstract][Full Text] [Related]
3. [Advances in Allogeneic Chimeric Antigen Receptor T Cells].
Zhao Q; Li F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Dec; 45(6):967-972. PubMed ID: 38173109
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
5. "Off-the-Shelf" Allogeneic CAR Cell Therapy-Neglected HvG Effect.
An Y; Jin X; Zhang H; Zhang M; Mahara S; Lu W; Zhao M
Curr Treat Options Oncol; 2023 May; 24(5):409-441. PubMed ID: 37010679
[TBL] [Abstract][Full Text] [Related]
6. 'Off-the-shelf' allogeneic CAR T cells: development and challenges.
Depil S; Duchateau P; Grupp SA; Mufti G; Poirot L
Nat Rev Drug Discov; 2020 Mar; 19(3):185-199. PubMed ID: 31900462
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.
Martínez Bedoya D; Dutoit V; Migliorini D
Front Immunol; 2021; 12():640082. PubMed ID: 33746981
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.
Khurana A; Lin Y
Curr Treat Options Oncol; 2022 Feb; 23(2):171-187. PubMed ID: 35212892
[TBL] [Abstract][Full Text] [Related]
9. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
10. Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There?
Watanabe N; Mamonkin M
Cancer J; 2021 Mar-Apr 01; 27(2):176-181. PubMed ID: 33750078
[TBL] [Abstract][Full Text] [Related]
11. Current approaches to develop "off-the-shelf" chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review.
Aparicio C; Acebal C; González-Vallinas M
Exp Hematol Oncol; 2023 Aug; 12(1):73. PubMed ID: 37605218
[TBL] [Abstract][Full Text] [Related]
12. [Development of allogeneic CAR T-cells].
Alcazer V; Depil S
Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities.
Vasic D; Lee JB; Leung Y; Khatri I; Na Y; Abate-Daga D; Zhang L
Sci Immunol; 2022 Apr; 7(70):eabl3642. PubMed ID: 35452255
[TBL] [Abstract][Full Text] [Related]
14. Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysis.
Chen S; Zhang Y; Fang C; Zhang N; Wang Y; Chen R; Li Y; Tu S
Crit Rev Oncol Hematol; 2022 Nov; 179():103807. PubMed ID: 36087853
[TBL] [Abstract][Full Text] [Related]
15. Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials.
Smirnov S; Petukhov A; Levchuk K; Kulemzin S; Staliarova A; Lepik K; Shuvalov O; Zaritskey A; Daks A; Fedorova O
Front Immunol; 2021; 12():780145. PubMed ID: 34975869
[TBL] [Abstract][Full Text] [Related]
16. CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy.
Wang Y; Wang L; Seo N; Okumura S; Hayashi T; Akahori Y; Fujiwara H; Amaishi Y; Okamoto S; Mineno J; Tanaka Y; Kato T; Shiku H
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446055
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Locatelli F; Del Bufalo F; Quintarelli C
Haematologica; 2024 Jun; 109(6):1689-1699. PubMed ID: 38832424
[TBL] [Abstract][Full Text] [Related]
18. Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies.
Dhakal B; Chhabra S; Savani BN; Hamadani M
Br J Haematol; 2022 Apr; 197(1):28-40. PubMed ID: 34671973
[TBL] [Abstract][Full Text] [Related]
19. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
20. Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice.
Hu X; Manner K; DeJesus R; White K; Gattis C; Ngo P; Bandoro C; Tham E; Chu EY; Young C; Wells F; Basco R; Friera A; Kangeyan D; Beauchesne P; Dowdle WE; Deuse T; Fry TJ; Foster AE; Schrepfer S
Nat Commun; 2023 Apr; 14(1):2020. PubMed ID: 37037829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]